Skip to content
CSE: XRX.CN 0.20 0.00 0.00%  
XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
    • Metabolic Syndrome / Diabetes
    • Hypertension
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Media
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search

XORTX Therapeutics Appoints Mr. Dave Matthews CFO

  • February 22, 2018July 25, 2018
  • by aaronbb

CALGARY, Alberta, Feb. 22, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Dave Matthews as Chief Financial Officer (“CFO”).   Dave Matthews brings over 25 years of life sciences experience to XORTX.

Dave Matthews began his career in the life science field as CFO of Allelix Biopharmaceuticals in 1990, followed by a number of notably successful life science companies including StressGen Biotechnologies, Aspreva Pharmaceuticals and GenomeDX Biosciences. As CFO and a key member of senior management for these companies, Dave was involved in raising over $300 million in financing and negotiated and operated numerous joint ventures, strategic alliances and license agreements.

Dr. Allen Davidoff, XORTX CEO stated, “We are very pleased that Dave has agreed to join XORTX.  He is a respected and experienced finance executive with international experience and a track record of building successful businesses. He brings a strong track record of initiation, closing and managing fund raising efforts as well as an impressive number of licensing deals with big pharmaceutical companies.  His outstanding record growing revenue and market capitalization of the companies he has been involved with, as a C-level executive, is remarkable and will be of immense benefit to XORTX”, and he added, “We also wish to thank John Meekison, who acted as interim CFO for XORTX since the Company’s founding making a significant contribution to the Company taking it through the listing process.  John is remaining with XORTX to assist with the transition.”

Dave Matthews commented, “XORTX is pursuing an interesting strategy focused on the acquisition of de-risked assets in orphan diseases. I look forward to working with the XORTX team to support the development of these assets to provide useful therapeutic options to patients.”

About XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease.  XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease.  Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease. Additional information on XORTX Therapeutics is available at www.XORTX.com.

For further information, please contact:
Erik Matthews, Corporate Communications & Investor Relations
+1-747-203-5240 or erik@xortx.com / ray@xortx.com

The CSE has neither approved nor disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Google+ (Opens in new window)

Related

APAC Resources Inc. and XORTX Pharma Corp. Announce Closing of Reverse Take-over, Financing, Consolidation and Name Change
XORTX Therapeutics Provides Corporate Update

Leave a Reply Cancel reply

Your email address will not be published.

Press Releases

  • XORTX Announces Positive Phase 2 Results in Type 2 Diabetic Nephropathy (T2DN) September 19, 2019
  • XORTX Highlights New Research on Polycystic Kidney Disease Awareness Day September 4, 2019
  • XORTX Announces Virtual Investor Conference Live Webcast July 30, 2019
  • XORTX Reports Annual & Special Meeting Results July 18, 2019
  • XORTX Shares Nature Nephrology Review July 15, 2019

Archives

  • 2012 Press Releases 3
  • 2014 Press Releases 2
  • 2015 Press Releases 1
  • 2017 Press Releases 2
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress